#United States #New York #Class Action #Semler Scientific #Pomerantz LLP

Pomerantz Law Firm Takes Action Against Semler Scientific, Inc.

On October 18, 2025, Pomerantz LLP announced significant developments concerning Semler Scientific, Inc., a publicly traded company on NASDAQ under the symbol SMLR. The firm has initiated a class action lawsuit against Semler, potentially affecting numerous investors who have faced financial losses related to their investments in the company. This legal move is not just an alert; it signifies broader concerns about the company's practices and its impact on shareholders.

Background of the Case

The class action lawsuit centers around allegations that Semler and certain officers or directors may have engaged in securities fraud and other unlawful business practices. Investors who purchased or acquired shares of Semler during the specified Class Period are urged to reach out to Pomerantz LLP to explore their options.

According to the firm, investors have until October 28, 2025, to formally request appointment as Lead Plaintiff in this class action. Those interested in participating can contact Danielle Peyton via email or phone, ensuring they include essential details such as their address and the number of shares they purchased.

Significant Events Leading to the Lawsuit

In a series of disclosures, Semler revealed alarming information impacting its stock performance. On February 28, 2025, the company filed its annual report for the fiscal year of 2024, which included a warning of a potential civil lawsuit from the U.S. Department of Justice (DOJ) related to its reimbursement claims concerning the QuantaFlo device, designed to diagnose peripheral artery disease. Notably, the DOJ had issued a civil investigative demand back in July 2017 regarding past claims made by Semler.

In a further blow, after unsuccessful settlement discussions with the DOJ in early 2025, Semler's share price dropped significantly. Following the announcement of the DOJ's potential actions, shares plummeted from $42.92 to $38.89, marking a 9.4% decrease within a single trading session. This downward spiral continued when, shortly after, Semler announced an agreement in principal to pay $29.75 million to settle all claims, leading to yet another decline in its stock value, closing at $31.00, a further drop of 9.88%.

The Role of Pomerantz LLP

Recognized as one of the elite firms in corporate and securities class action litigation, Pomerantz LLP has a long-standing reputation for advocating on behalf of shareholders who have been victims of corporate misconduct and breaches of fiduciary duty. Founded by the late Abraham L. Pomerantz, the firm is now over 85 years old and continues its mission of securing justice for investors. The firm maintains offices across major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, which allows them to engage in multi-national claims effectively.

Pomerantz has a rich history of successful recoveries for class members, often amounting to millions of dollars. Investors interested in joining the class action against Semler Scientific are encouraged to visit www.pomerantzlaw.com to obtain further details regarding this unfolding event.

Conclusion

The initiation of this lawsuit reflects not just a legal challenge against Semler Scientific, but also signifies a potential shift in accountability and transparency within the company’s operations. As more investors become aware of the implications of the allegations against Semler, it will be interesting to monitor the outcome of this class action lawsuit, as it may set a precedent for similar cases in the future. Investors should act promptly and reach out to Pomerantz LLP if they believe they have been adversely affected by Semler's actions.